Enovis (NYSE:ENOV) Updates FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.250-3.350 for the period, compared to the consensus EPS estimate of 3.180. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ENOV shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Canaccord Genuity Group lowered their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th. BTIG Research began coverage on shares of Enovis in a research report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target for the company. Finally, Evercore ISI reissued an “outperform” rating on shares of Enovis in a research note on Monday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Enovis Stock Down 1.7%

NYSE:ENOV opened at $24.24 on Thursday. The firm has a 50-day simple moving average of $27.98 and a two-hundred day simple moving average of $29.75. The firm has a market cap of $1.39 billion, a P/E ratio of -1.02 and a beta of 1.52. Enovis has a fifty-two week low of $23.58 and a fifty-two week high of $49.38. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $548.91 million during the quarter, compared to the consensus estimate of $538.61 million. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 earnings per share. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Kleckner acquired 2,468 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was bought at an average cost of $30.32 per share, for a total transaction of $74,829.76. Following the purchase, the insider directly owned 12,302 shares of the company’s stock, valued at approximately $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Enovis

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its position in shares of Enovis by 1.2% during the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after acquiring an additional 621 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC lifted its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in Enovis by 10.8% in the second quarter. Benjamin Edwards Inc. now owns 15,207 shares of the company’s stock valued at $477,000 after acquiring an additional 1,487 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Enovis by 1.5% during the 3rd quarter. Swiss National Bank now owns 110,700 shares of the company’s stock valued at $3,359,000 after purchasing an additional 1,600 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.